JP2016523087A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016523087A5 JP2016523087A5 JP2016521893A JP2016521893A JP2016523087A5 JP 2016523087 A5 JP2016523087 A5 JP 2016523087A5 JP 2016521893 A JP2016521893 A JP 2016521893A JP 2016521893 A JP2016521893 A JP 2016521893A JP 2016523087 A5 JP2016523087 A5 JP 2016523087A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- compound according
- alkyl
- compound
- nucleoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 262
- 239000002777 nucleoside Substances 0.000 claims description 92
- 125000005647 linker group Chemical group 0.000 claims description 89
- 108091034117 Oligonucleotide Proteins 0.000 claims description 77
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 48
- 125000003835 nucleoside group Chemical group 0.000 claims description 35
- 108010056301 Apolipoprotein C-III Proteins 0.000 claims description 31
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 30
- 102000030169 Apolipoprotein C-III Human genes 0.000 claims description 28
- 229910052736 halogen Inorganic materials 0.000 claims description 28
- 150000002367 halogens Chemical class 0.000 claims description 28
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 25
- 230000000295 complement effect Effects 0.000 claims description 17
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 16
- 230000004048 modification Effects 0.000 claims description 16
- 238000012986 modification Methods 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 14
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 14
- 125000000304 alkynyl group Chemical group 0.000 claims description 13
- -1 furanosyl nucleoside Chemical class 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 9
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 150000004713 phosphodiesters Chemical class 0.000 claims description 7
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 6
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 5
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical group NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 4
- 229930024421 Adenine Chemical group 0.000 claims description 4
- 229960000643 adenine Drugs 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 229940104302 cytosine Drugs 0.000 claims description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 3
- 229940113082 thymine Drugs 0.000 claims description 3
- 229940035893 uracil Drugs 0.000 claims description 3
- YIMATHOGWXZHFX-WCTZXXKLSA-N (2r,3r,4r,5r)-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolane-2,4-diol Chemical compound COCCO[C@H]1[C@H](O)O[C@H](CO)[C@H]1O YIMATHOGWXZHFX-WCTZXXKLSA-N 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 150000003573 thiols Chemical class 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 230000000087 stabilizing effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 1
- 125000004437 phosphorous atom Chemical group 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 108091081021 Sense strand Proteins 0.000 description 23
- 230000000692 anti-sense effect Effects 0.000 description 22
- 230000008685 targeting Effects 0.000 description 19
- 125000000217 alkyl group Chemical group 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 12
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 0 CCC(C(C)C1O)OCC1(NC(C)=O)OCCCCC(NCCCNC(CCOCC(COCCC(NCCCNC(CCCCO[C@](*C(*)[C@](C)C1)C1NC(C)=O)=O)O)(COCCC(NCCCNC(CCCCO[C@@]1O*(C)C(*)C1NC(C)=O)=O)=O)NC(CCCC(NCCCCCCO[C@@]([C@@](*)OC1CONC)[C@@]1O)=O)=O)=O)=O Chemical compound CCC(C(C)C1O)OCC1(NC(C)=O)OCCCCC(NCCCNC(CCOCC(COCCC(NCCCNC(CCCCO[C@](*C(*)[C@](C)C1)C1NC(C)=O)=O)O)(COCCC(NCCCNC(CCCCO[C@@]1O*(C)C(*)C1NC(C)=O)=O)=O)NC(CCCC(NCCCCCCO[C@@]([C@@](*)OC1CONC)[C@@]1O)=O)=O)=O)=O 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 241000764238 Isis Species 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000012739 integrated shape imaging system Methods 0.000 description 6
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical class N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- RUVRGYVESPRHSZ-UHFFFAOYSA-N 2-[2-(2-azaniumylethoxy)ethoxy]acetate Chemical compound NCCOCCOCC(O)=O RUVRGYVESPRHSZ-UHFFFAOYSA-N 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 235000011007 phosphoric acid Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 3
- 102100030970 Apolipoprotein C-III Human genes 0.000 description 3
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 3
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 125000001033 ether group Chemical group 0.000 description 3
- ALBYIUDWACNRRB-UHFFFAOYSA-N hexanamide Chemical group CCCCCC(N)=O ALBYIUDWACNRRB-UHFFFAOYSA-N 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 2
- 229960002684 aminocaproic acid Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 102000001493 Cyclophilins Human genes 0.000 description 1
- 108010068682 Cyclophilins Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361838190P | 2013-06-21 | 2013-06-21 | |
| US61/838,190 | 2013-06-21 | ||
| US201361871683P | 2013-08-29 | 2013-08-29 | |
| US61/871,683 | 2013-08-29 | ||
| PCT/US2014/043731 WO2014205451A2 (en) | 2013-06-21 | 2014-06-23 | Compositions and methods for modulation of target nucleic acids |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020029006A Division JP2020099335A (ja) | 2013-06-21 | 2020-02-25 | 標的核酸を調節するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016523087A JP2016523087A (ja) | 2016-08-08 |
| JP2016523087A5 true JP2016523087A5 (enExample) | 2017-08-03 |
| JP6694382B2 JP6694382B2 (ja) | 2020-05-13 |
Family
ID=52105553
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016521893A Active JP6694382B2 (ja) | 2013-06-21 | 2014-06-23 | 標的核酸を調節するための組成物および方法 |
| JP2020029006A Withdrawn JP2020099335A (ja) | 2013-06-21 | 2020-02-25 | 標的核酸を調節するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020029006A Withdrawn JP2020099335A (ja) | 2013-06-21 | 2020-02-25 | 標的核酸を調節するための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20160122761A1 (enExample) |
| EP (3) | EP3011028B1 (enExample) |
| JP (2) | JP6694382B2 (enExample) |
| AU (2) | AU2014284152B2 (enExample) |
| CA (1) | CA2916252A1 (enExample) |
| WO (1) | WO2014205451A2 (enExample) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0923225A2 (pt) | 2008-12-02 | 2016-10-04 | Chiralgen Ltd | metodo para sintese de acidos nucleicos modificados no atomo de fosforo |
| EP2451461A4 (en) | 2009-07-06 | 2013-05-29 | Ontorii Inc | NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF |
| DK2620428T3 (da) | 2010-09-24 | 2019-07-01 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
| CN107365339A (zh) | 2011-07-19 | 2017-11-21 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
| WO2014010250A1 (en) | 2012-07-13 | 2014-01-16 | Chiralgen, Ltd. | Asymmetric auxiliary group |
| PL2992098T3 (pl) | 2013-05-01 | 2019-09-30 | Ionis Pharmaceuticals, Inc. | Kompozycje i sposoby modulowania ekspresji hbv i ttr |
| WO2015006740A2 (en) * | 2013-07-11 | 2015-01-15 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide-ligand conjugates and process for their preparation |
| EP3094728B1 (en) | 2014-01-16 | 2022-03-09 | Wave Life Sciences Ltd. | Chiral design |
| WO2015168618A2 (en) | 2014-05-01 | 2015-11-05 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating growth hormone receptor expression |
| CR20160554A (es) * | 2014-05-01 | 2017-03-07 | Ionis Pharmaceuticals Inc | Composiciones y métodos para modular la expresión del factor b del complemento |
| US10570169B2 (en) | 2014-05-22 | 2020-02-25 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| EP3151839A4 (en) * | 2014-06-06 | 2018-02-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds |
| AU2015329974B2 (en) * | 2014-10-10 | 2019-06-20 | F. Hoffmann-La Roche Ag | GaINAc phosphoramidites, nucleic acid conjugates thereof and their use |
| AU2016332900C1 (en) | 2015-09-29 | 2024-07-04 | Amgen Inc. | ASGR inhibitors |
| AU2016349625B2 (en) | 2015-11-06 | 2022-07-07 | Ionis Pharmaceuticals, Inc. | Modulating apolipoprotein (a) expression |
| LT4119569T (lt) * | 2015-11-06 | 2024-09-25 | Ionis Pharmaceuticals, Inc. | Konjuguoti priešprasmiai junginiai, skirti panaudoti terapijoje |
| TWI859114B (zh) | 2016-04-11 | 2024-10-21 | 加拿大商艾爾布圖斯生技公司 | 靶向組合物 |
| UY37376A (es) | 2016-08-26 | 2018-03-23 | Amgen Inc | Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso |
| WO2018067900A1 (en) * | 2016-10-06 | 2018-04-12 | Ionis Pharmaceuticals, Inc. | Method of conjugating oligomeric compounds |
| US20180193270A1 (en) | 2016-11-29 | 2018-07-12 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| CN108239644B (zh) * | 2016-12-23 | 2021-05-28 | 苏州瑞博生物技术股份有限公司 | 一种小干扰核酸和药物组合物及其用途 |
| CA3059426A1 (en) | 2017-04-11 | 2018-10-18 | Arbutus Biopharma Corporation | Targeted compositions |
| SG11201912178VA (en) * | 2017-09-11 | 2020-01-30 | Arrowhead Pharmaceuticals Inc | Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3) |
| SG11202002149XA (en) | 2017-09-14 | 2020-04-29 | Janssen Biopharma Inc | Galnac derivatives |
| WO2019105414A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN118291456A (zh) | 2017-12-01 | 2024-07-05 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| HRP20250277T1 (hr) | 2017-12-01 | 2025-05-09 | Suzhou Ribo Life Science Co., Ltd. | Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba |
| JP7360716B2 (ja) | 2017-12-01 | 2023-10-13 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用 |
| CN110944675B9 (zh) | 2017-12-01 | 2024-08-09 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| AR113490A1 (es) | 2017-12-12 | 2020-05-06 | Amgen Inc | CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LAS MISMAS |
| WO2020038377A1 (zh) | 2018-08-21 | 2020-02-27 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的药物组合物和缀合物及其用途 |
| US12049620B2 (en) | 2018-09-11 | 2024-07-30 | Amgen Inc. | Purification methods for guanine-rich oligonucleotides |
| JP7376952B2 (ja) * | 2018-09-30 | 2023-11-09 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | ｓｉＲＮＡ複合体及びその調製方法と使用 |
| AU2019380628B2 (en) * | 2018-11-13 | 2024-10-31 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of LPA in a cell |
| GB2579253A (en) * | 2018-11-28 | 2020-06-17 | Pedanius Therapeutics Ltd | Antibacterial antisense agents |
| CA3121510A1 (en) | 2018-12-10 | 2020-06-18 | Amgen Inc. | Rnai constructs for inhibiting pnpla3 expression and methods of use thereof |
| SG11202105900UA (en) | 2018-12-10 | 2021-07-29 | Amgen Inc | CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF |
| JP7507495B2 (ja) | 2018-12-28 | 2024-06-28 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| CN113227376B (zh) | 2019-05-22 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| JP7610848B2 (ja) | 2019-05-22 | 2025-01-09 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
| CN113286888B (zh) | 2019-05-22 | 2023-12-22 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| CN113795582B (zh) | 2019-05-24 | 2024-05-24 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| SG11202113112WA (en) | 2019-05-30 | 2021-12-30 | Amgen Inc | Rnai constructs for inhibiting scap expression and methods of use thereof |
| CA3143047A1 (en) | 2019-06-25 | 2020-12-30 | Amgen Inc. | Purification methods for carbohydrate-linked oligonucleotides |
| US20220340911A1 (en) | 2019-08-13 | 2022-10-27 | Amgen Inc. | Rnai constructs for inhibiting slc30a8 expression and methods of use thereof |
| KR20220062517A (ko) * | 2019-08-15 | 2022-05-17 | 아이오니스 파마수티컬즈, 인코포레이티드 | 결합 변형된 올리고머 화합물 및 이의 용도 |
| IL290766B2 (en) * | 2019-09-03 | 2026-03-01 | Arcturus Therapeutics Inc | Administration of therapeutically active conjugates mediated by asialoglycoprotein receptor |
| WO2021054370A1 (ja) * | 2019-09-18 | 2021-03-25 | 国立大学法人東京医科歯科大学 | 核酸複合体 |
| JP7827623B2 (ja) | 2019-12-09 | 2026-03-10 | アムジエン・インコーポレーテツド | ＬＰＡ発現を阻害するためのＲＮＡｉコンストラクト及び方法 |
| CN115397989A (zh) | 2020-02-18 | 2022-11-25 | 阿尔尼拉姆医药品有限公司 | 载脂蛋白C3(APOC3)iRNA组合物及其使用方法 |
| EP4126967A1 (en) | 2020-03-23 | 2023-02-08 | Amgen Inc. | Monoclonal antibodies to chemically-modified nucleic acids and uses thereof |
| US20230279399A1 (en) | 2020-06-01 | 2023-09-07 | Amgen Inc. | Rnai constructs for inhibiting hsd17b13 expression and methods of use thereof |
| EP4196584A2 (en) | 2020-08-13 | 2023-06-21 | Amgen Inc. | Rnai constructs and methods for inhibiting marc1 expression |
| US20240092819A1 (en) * | 2020-10-20 | 2024-03-21 | Sanofi | Novel ligands for asialoglycoprotein receptor |
| KR20230104200A (ko) | 2020-11-05 | 2023-07-07 | 암젠 인크 | LPA-표적화된 RNAi 작제물을 이용하여 죽상경화성 심혈관질환을 치료하는 방법 |
| EP4175964A1 (en) * | 2021-01-30 | 2023-05-10 | E-Therapeutics plc | Conjugated oligonucleotide compounds, methods of making and uses thereof |
| CN117355534B (zh) | 2021-01-30 | 2026-05-01 | 唐格拉姆治疗公司 | 缀合寡核苷酸化合物、其制备方法和用途 |
| WO2022162161A1 (en) * | 2021-01-30 | 2022-08-04 | E-Therapeutics Plc | Conjugated oligonucleotide compounds, methods of making and uses thereof |
| CN115850358B (zh) * | 2021-03-08 | 2026-04-24 | 南京吉迈生物技术有限公司 | GalNAc簇亚磷酰胺和靶向治疗性核苷 |
| WO2022246195A1 (en) * | 2021-05-20 | 2022-11-24 | Olix Us, Inc. | Functional moieties and their uses and synthetic preparation |
| CN117580953B (zh) * | 2021-07-16 | 2025-07-18 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN118019566A (zh) | 2021-09-30 | 2024-05-10 | 美国安进公司 | 分离富含鸟嘌呤的寡核苷酸的分子物质的方法 |
| US20250011779A1 (en) | 2021-10-05 | 2025-01-09 | Amgen Inc. | Compositions and methods for enhancing gene silencing activity of oligonucleotide compounds |
| CA3235262A1 (en) | 2021-10-22 | 2023-04-27 | Amgen Inc. | Rnai constructs for inhibiting gpam expression and methods of use thereof |
| CA3235963A1 (en) * | 2021-11-15 | 2023-05-19 | Novartis Ag | Branched triple lipid-modified nucleic acid compounds |
| JP7877458B2 (ja) | 2021-12-01 | 2026-06-22 | ディセルナ ファーマシューティカルズ インコーポレイテッド | Ａｐｏｃ３発現を調節するための組成物及び方法 |
| MX2024010419A (es) | 2022-02-25 | 2024-09-05 | Amgen Inc | Metodos de preparacion de sustancias farmacologicas liquidas de alta concentracion. |
| CA3262515A1 (en) | 2022-07-25 | 2024-02-01 | Amgen Inc. | ARNI CONSTRUCTIONS AND METHODS FOR INHIBITING FAM13A EXPRESSION |
| KR20250119645A (ko) | 2022-12-16 | 2025-08-07 | 암젠 인크 | Ttr 발현을 억제하기 위한 rnai 구성체 및 이의 사용 방법 |
| KR20260089666A (ko) * | 2023-09-14 | 2026-06-15 | 아이오니스 파마수티컬즈, 인코포레이티드 | Apociii 발현을 감소시키기 위한 화합물 및 방법 |
| WO2025252196A1 (zh) * | 2024-06-06 | 2025-12-11 | 苏州吉玛基因股份有限公司 | 一种用于抑制补体成分C5表达的siRNA及其应用和产品 |
| WO2025259726A1 (en) | 2024-06-11 | 2025-12-18 | Amgen Inc. | Methods for separating diastereomers of double-stranded oligonucleotides |
| WO2025260042A1 (en) | 2024-06-14 | 2025-12-18 | Amgen Inc. | Rnai constructs and methods for inhibiting cnr1 expression |
| WO2026006275A2 (en) | 2024-06-26 | 2026-01-02 | Amgen Inc. | Rnai constructs and methods for inhibiting expression of inhbe |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US23861A (en) * | 1859-05-03 | Improvement in revolving fire-arms | ||
| US2699808A (en) | 1944-10-06 | 1955-01-18 | Mark W Lowe | Apparatus for peeling tomatoes |
| US2699508A (en) | 1951-12-21 | 1955-01-11 | Selectronics Inc | Method of mounting and construction of mounting for low frequency piezoelectric crystals |
| US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
| US5367066A (en) | 1984-10-16 | 1994-11-22 | Chiron Corporation | Oligonucleotides with selectably cleavable and/or abasic sites |
| FR2575751B1 (fr) | 1985-01-08 | 1987-04-03 | Pasteur Institut | Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques |
| EP0366685B1 (en) | 1987-06-24 | 1994-10-19 | Howard Florey Institute Of Experimental Physiology And Medicine | Nucleoside derivatives |
| US5175273A (en) | 1988-07-01 | 1992-12-29 | Genentech, Inc. | Nucleic acid intercalating agents |
| US5134066A (en) | 1989-08-29 | 1992-07-28 | Monsanto Company | Improved probes using nucleosides containing 3-dezauracil analogs |
| US5130302A (en) | 1989-12-20 | 1992-07-14 | Boron Bilogicals, Inc. | Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same |
| US5459255A (en) | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
| US5681941A (en) | 1990-01-11 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
| US5587470A (en) | 1990-01-11 | 1996-12-24 | Isis Pharmaceuticals, Inc. | 3-deazapurines |
| JPH0874B2 (ja) | 1990-07-27 | 1996-01-10 | アイシス・ファーマシューティカルス・インコーポレーテッド | 遺伝子発現を検出および変調するヌクレアーゼ耐性、ピリミジン修飾オリゴヌクレオチド |
| US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
| US5594121A (en) | 1991-11-07 | 1997-01-14 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified purines |
| TW393513B (en) | 1991-11-26 | 2000-06-11 | Isis Pharmaceuticals Inc | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines |
| US5484908A (en) | 1991-11-26 | 1996-01-16 | Gilead Sciences, Inc. | Oligonucleotides containing 5-propynyl pyrimidines |
| EP0637965B1 (en) | 1991-11-26 | 2002-10-16 | Isis Pharmaceuticals, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines |
| WO1994014226A1 (en) | 1992-12-14 | 1994-06-23 | Honeywell Inc. | Motor system with individually controlled redundant windings |
| ES2128535T3 (es) | 1993-05-12 | 1999-05-16 | Novartis Ag | Nucleosidos y oligonucleotidos con grupos 2'-eter. |
| US5502177A (en) | 1993-09-17 | 1996-03-26 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
| US5457187A (en) | 1993-12-08 | 1995-10-10 | Board Of Regents University Of Nebraska | Oligonucleotides containing 5-fluorouracil |
| US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
| US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
| TW520293B (en) | 1995-11-22 | 2003-02-11 | Univ Johns Hopkins Med | Delivery system to enhance cellular uptake of biomolecules |
| US5656408A (en) | 1996-04-29 | 1997-08-12 | Xerox Corporation | Coated carrier particles |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US6300319B1 (en) | 1998-06-16 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Targeted oligonucleotide conjugates |
| ATE356824T1 (de) | 1999-05-04 | 2007-04-15 | Santaris Pharma As | L-ribo-lna analoge |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| CN100406065C (zh) | 2000-12-01 | 2008-07-30 | 细胞工厂治疗公司 | 糖基化/半乳糖基化肽、双官能接头和核苷酸单体/多聚体的缀合物以及相关的组合物和使用方法 |
| CA2504694C (en) | 2002-11-05 | 2013-10-01 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| US8604183B2 (en) | 2002-11-05 | 2013-12-10 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
| US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
| US7723509B2 (en) | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
| WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
| DK1661905T3 (da) | 2003-08-28 | 2012-07-23 | Takeshi Imanishi | Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype |
| WO2005027962A1 (en) | 2003-09-18 | 2005-03-31 | Isis Pharmaceuticals, Inc. | 4’-thionucleosides and oligomeric compounds |
| WO2006031461A2 (en) | 2004-09-09 | 2006-03-23 | Isis Pharmaceuticals, Inc. | Pyrrolidinyl groups for attaching conjugates to oligomeric compounds |
| US20060148740A1 (en) | 2005-01-05 | 2006-07-06 | Prosensa B.V. | Mannose-6-phosphate receptor mediated gene transfer into muscle cells |
| US7569686B1 (en) | 2006-01-27 | 2009-08-04 | Isis Pharmaceuticals, Inc. | Compounds and methods for synthesis of bicyclic nucleic acid analogs |
| DE602007009487D1 (de) | 2006-01-27 | 2010-11-11 | Isis Pharmaceutical Inc | 6-modifizierte bicyclische nukleinsäureanaloga |
| US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
| CA2651453C (en) | 2006-05-11 | 2014-10-14 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
| US20100190837A1 (en) | 2007-02-15 | 2010-07-29 | Isis Pharmaceuticals, Inc. | 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom |
| DK2170917T3 (da) | 2007-05-30 | 2012-10-08 | Isis Pharmaceuticals Inc | N-Substituerede bicycliske nukleinsyreanaloge med aminomethylenbro |
| WO2008154401A2 (en) | 2007-06-08 | 2008-12-18 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
| AU2008272918B2 (en) | 2007-07-05 | 2012-09-13 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| EP2229186A2 (en) | 2007-12-04 | 2010-09-22 | Alnylam Pharmaceuticals Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| US8575123B2 (en) | 2008-04-11 | 2013-11-05 | Tekmira Pharmaceuticals Corporation | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| WO2009143369A2 (en) | 2008-05-22 | 2009-11-26 | Isis Pharmaceuticals, Inc. | Method of preparing nucleosides and analogs thereof without using chromatography |
| WO2010036698A1 (en) | 2008-09-24 | 2010-04-01 | Isis Pharmaceuticals, Inc. | Substituted alpha-l-bicyclic nucleosides |
| EP2358397B1 (en) | 2008-10-24 | 2020-01-01 | Ionis Pharmaceuticals, Inc. | 5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom |
| EP2447274B1 (en) | 2008-10-24 | 2017-10-04 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
| AT507215B1 (de) | 2009-01-14 | 2010-03-15 | Boehler Edelstahl Gmbh & Co Kg | Verschleissbeständiger werkstoff |
| EP2405921A4 (en) | 2009-01-26 | 2013-05-22 | Protiva Biotherapeutics Inc | COMPOSITIONS AND METHODS FOR VAPORING APOLIPOPROTIEN C-III EXPRESSION |
| WO2011115818A1 (en) | 2010-03-17 | 2011-09-22 | Isis Pharmaceuticals, Inc. | 5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom |
| WO2011139702A2 (en) * | 2010-04-28 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Modified nucleosides and oligomeric compounds prepared therefrom |
| US9290760B2 (en) | 2010-09-15 | 2016-03-22 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
| US8603994B2 (en) * | 2010-11-11 | 2013-12-10 | Valted, Llc | Transcriptional repression leading to Parkinson's disease |
| SG194671A1 (en) * | 2011-04-27 | 2013-12-30 | Isis Pharmaceuticals Inc | Modulation of apolipoprotein ciii (apociii) expression |
| EP2723756B1 (en) | 2011-06-21 | 2020-03-11 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes |
| US10023861B2 (en) * | 2011-08-29 | 2018-07-17 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
| EP2751269B1 (en) * | 2011-08-29 | 2016-03-23 | Ionis Pharmaceuticals, Inc. | Methods and compounds useful in conditions related to repeat expansion |
| US9984408B1 (en) | 2012-05-30 | 2018-05-29 | Amazon Technologies, Inc. | Method, medium, and system for live video cooperative shopping |
| KR20200123263A (ko) | 2013-02-14 | 2020-10-28 | 아이오니스 파마수티컬즈, 인코포레이티드 | 지질단백질 리파제 결핍 (lpld) 모집단에서 아포지질단백질 c-iii (apociii) 발현의 조절 |
| US9778708B1 (en) | 2016-07-18 | 2017-10-03 | Lenovo Enterprise Solutions (Singapore) Pte. Ltd. | Dual sided latching retainer for computer modules |
-
2014
- 2014-06-23 WO PCT/US2014/043731 patent/WO2014205451A2/en not_active Ceased
- 2014-06-23 CA CA2916252A patent/CA2916252A1/en not_active Abandoned
- 2014-06-23 EP EP14813192.3A patent/EP3011028B1/en active Active
- 2014-06-23 AU AU2014284152A patent/AU2014284152B2/en active Active
- 2014-06-23 EP EP20173519.8A patent/EP3730619A1/en not_active Withdrawn
- 2014-06-23 JP JP2016521893A patent/JP6694382B2/ja active Active
- 2014-06-23 US US14/898,873 patent/US20160122761A1/en not_active Abandoned
- 2014-06-23 EP EP19179457.7A patent/EP3564374A1/en not_active Withdrawn
-
2018
- 2018-11-05 US US16/181,206 patent/US20190127737A1/en not_active Abandoned
-
2019
- 2019-12-23 AU AU2019284048A patent/AU2019284048A1/en not_active Withdrawn
-
2020
- 2020-02-25 JP JP2020029006A patent/JP2020099335A/ja not_active Withdrawn
- 2020-03-09 US US16/813,241 patent/US20200270609A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6884250B2 (ja) | ペプチドオリゴヌクレオチドコンジュゲート | |
| JP7007304B2 (ja) | Ｂ型肝炎感染症治療用のＰＡＰＤ５又はＰＡＰＤ７のｍＲＮＡ減少用核酸分子 | |
| JP2021048886A (ja) | 修飾されたサブユニット間結合および／または末端基を有するオリゴヌクレオチドアナログ | |
| JP2016513976A5 (enExample) | ||
| AU2021203174A1 (en) | Compositions and methods for modulating RNA | |
| JP7348922B2 (ja) | Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子 | |
| US10758558B2 (en) | Hybrid oligonucleotides and uses thereof | |
| JP2019503394A5 (enExample) | ||
| US20150232858A1 (en) | Euchromatic region targeting methods for modulating gene expression | |
| JP7515400B2 (ja) | Ｂ型肝炎ウイルス感染を治療するためのｆｕｂｐ１阻害剤の使用 | |
| US20150225722A1 (en) | Methods for selective targeting of heterochromatin forming non-coding rna | |
| JP2020099335A (ja) | 標的核酸を調節するための組成物および方法 | |
| JP6326433B2 (ja) | 三環式ヌクレオシド及びそれから調製されるオリゴマー化合物 | |
| JP2015504650A5 (enExample) | ||
| JP2016502858A5 (enExample) | ||
| JP2018529732A5 (enExample) | ||
| JP2007509040A5 (enExample) | ||
| JP2018507711A5 (enExample) | ||
| JP2013532122A5 (enExample) | ||
| RU2016146819A (ru) | Композиции и способы модулирования экспрессии рецептора гормона роста | |
| RU2014121304A (ru) | Ингибирование экспрессии вирусных генов | |
| CN119662650A (zh) | 用于抑制α-ENaC表达的RNAi剂及使用方法 | |
| JP2021515784A5 (enExample) | ||
| JP2021524277A (ja) | Ｒｔｅｌ１発現の調節用のオリゴヌクレオチド | |
| JP2018518167A5 (enExample) |